Recently, pharma based anti-obesity strategies, have been revolutionised by the application of Glucagon-Like-Peptide 1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor agonists. This evidence concerns the gene GCG and Obesity.